Irritable bowel syndrome (IBS) is a common chronic disorder that is associated with significant disability and health care costs. The purpose of this paper is to review and assess published randomised controlled trials examining the clinical eVectiveness of interventions for IBS for 1987-1998. A literature search was conducted to identify randomised controlled trials of IBS treatments: 45 studies were identified that described randomised controlled trials and of these, six fulfilled all three criteria used to assess the quality of randomised controlled trials, as described by Jadad and colleagues.
Introduction
IBS is the most common functional bowel disorder and aVects about 20% of all people at any one time. 2 3 It is a condition characterised by abdominal pain associated with defecation, or a change in bowel habit and with features of disordered defecation and distension in the absence of any demonstrable abnormality. 2 Three subgroups exist: one third of patients suVer constipation, one third suVer diarrhoea, and the rest suVer alternating constipation and diarrhoea. 3 4 While patients with symptoms of IBS represent 20-50% of referrals to gastroenterologists, there are many who do not seek medical attention. 5 The burden of illness associated with IBS is considerable. One recent study in the UK 6 found IBS suVerers to report substantially lower quality of life scores, as measured by the SF36, than the control group. SuVerers also used health service resources to a greater extent and missed more days oV work than the control group.
A number of pharmaceutical companies have new drugs in development to treat IBS and there is interest in the use of psychotherapy, either alone or in conjunction with other therapy. Before these therapies are adopted it is important to assess the evidence on the eVectiveness of what is already available. It is highly likely that in the very near future a crop of new eYcacy studies will be published.
This paper therefore reviews the quality and direction of current evidence.
Methods

LITERATURE SEARCH
To identify the studies used in this review, the following databases were searched: Cochrane Library, Database of Abstracts of Reviews of EVectiveness (DARE), Medline, and Embase. The key words "colonic diseases", "functional", and "clinical trials" were used. General reviews, meta-analyses, and references from published randomised controlled trials (RCTs) were also used. Trials published between 1987 and 1998 in English, French, German, Italian, and Spanish were included. INCLUSION CRITERIA In order to be included in this review, a study had to have been published in a peer reviewed journal and to be judged by the authors of this review to be truly randomised. RCTs dealing with bulking agents, anticholinergics/ antispasmodics, antidiarrhoeals, prokinetic drugs, antidepressants including psychotropic drugs, serotonergic antagonist drugs, combinations of drugs, as well as recent and miscellaneous drugs were included. Trials comparing diVerent treatments without placebo control groups were also included. High fibre diet or a fibre supplementation taken in all randomised groups was also included. EXCLUSION 
CRITERIA
Trials published as abstracts or letters, or not clearly randomised were excluded. RCTs which analysed drugs with only a pharmacological eVect on motility were also excluded.
ASSESSMENT OF RCTS
In the RCTs identified, the following points were assessed: x sample size x number of dropouts x extent to which blinding was used x intervention x outcome measures such as global assessment of symptoms by the patient or physician, abdominal pain, constipation, diarrhoea, or abdominal distension.
Results
A total of 227 studies were identified between 1987 and 1998. There was some duplication of the studies identified from the various databases. Of these 227 studies, 93 described trials. Only 45 trials were used in this review as the remaining 48 were either not randomised or studies of gut motility. The interventions described included: bulking agents, anticholinergics/antispamodics, antidiarrhoeals, serotonergic drugs, antidepressants/psychotropic drugs, prokinetic drugs, as well as recent and miscellaneous drugs. These 45 studies are outlined in table 1. The quality of these 45 trials was assessed according to the simple criteria laid down by Jadad and colleagues 1 : whether the method of randomisation was described; whether the study was double blinded; and whether a description of withdrawals and dropouts from the study was included. It is possible that these studies used appropriate methods of randomisation but failed to describe them. Other more complicated critical appraisal checklists are available. 52 However, it was felt that very few trials would have been included in a more rigorous list of criteria. Table 2 summarises the characteristics of the 45 trials to which the Jadad criteria were applied. When applying the criteria, only six of the RCTs identified provided adequate information, 10 11 17 22 30 31 highlighting the lack of well designed and well reported trials of IBS. Of the six studies meeting the criteria, two were of bulking agents, 10 11 two were of antispasmodic or anticholinergic drugs, 17 22 and two were of antidepressant/ psychotropic drugs. 30 31 The fact that only six studies met even such a relatively minimal set of criteria suggests that the quality of the current evidence is not good. Because so few studies met the criteria, further discussion has not been confined to them but has embraced all 45 studies listed in table 2.
BULKING AGENTS
Seven double blind, placebo controlled trials of bulking agents are listed in table 1. The study carried out by Snook and Shepherd 11 of 80 patients in a double blind, crossover trial not only found bran supplementation to be no more eVective than placebo in improving individual symptoms of IBS but for wind related symptoms it was significantly less eVective. Prior and Whorwell 10 examined a total of 80 patients and found significant diVerences in bowel habit and transit time in those with constipation and in overall well being between the groups receiving ispaghula husk and placebo.
The appears to be some evidence that bulking agents may be eVective in treating constipation associated with IBS although there is little reason to believe that they are eVective for the entire IBS symptom complex.
ANTISPASMODICS/ANTICHOLINERGIC DRUGS
Twelve trials of antispasmodics (most of which were anticholinergics) were identified. Passaretti and colleagues 22 carried out a study on 40 patients who were given cimetropium bromide (50 mg three times daily) or placebo for one month and found that the antispasmodic significantly (p<0.01) shortened whole gut transit time in patients with prolonged transit time. It also improved the global clinical condition compared with placebo (p=0.029). These findings were further supported by Dobrilla and colleagues 17 in a three month study. In this study of 70 consecutive outpatients, cimetropium bromide (50 mg three times daily) was found to significantly reduce pain as well as the number of pain episodes compared with placebo at the end of three months (p<0.001). Moreover, 89% of patients treated with cimetropium considered themselves to be globally improved compared with 69% in the placebo group (p=0.039).
ANTIDEPRESSANT/PSYCHOTROPIC DRUGS
In general, antidepressants are used for patients with persistent painful symptoms with or without associated psychiatric morbidity. It has been suggested that the tricyclic antidepressants may have a beneficial eVect in IBS mediated via a mechanism other than their antidepressant activity. 53 Four trials of antidepressants were reported. Alevizos and colleagues 30 described a study comparing the antidepressant amineptine 200 mg/day with placebo for six weeks in 40 patients who satisfied the criteria for IBS and scored at least 15 in the 24 item Hamilton depression scale (HAM-D). The study found that amineptine produced significantly greater improvement for the total Hamilton score than patients who received placebo at the end of the trial period. Amineptine was more eVective in treating depressed mood, retardation, and cognitive dysfunction. Barbier and colleagues 31 studied the eYcacy and safety of a combination of buzepide metiotide and haloperidol for two months in 224 patients. This combination resulted in improvement in frequency of symptoms and intensity of the most frequent symptoms, abdominal pain and distension, compared with placebo. Patients receiving the drug combination also reported greater global improvement than the placebo group.
Discussion
DIAGNOSTIC CRITERIA (ENTRY CRITERIA) USED IN TRIALS A major consideration in the design of a treatment trial is characterisation of the entity to be studied as this will determine the nature of the patients who are enrolled. Unless physiological markers are found, the diagnosis of IBS is usually made on the basis of clinical history (the presence of abdominal pain, abdominal distension, and a disordered bowel habit) and exclusion of organic disease. Criteria outlined by Manning and colleagues 54 help to diagnose the condition more positively, thus allowing studies on the disorder to be more comparable. The more recently defined "Rome criteria" 55 provide an international consensus on diagnosis and adequate entry criteria for a clinical trial in IBS. Of the 47 trials identified, six used Manning criteria, 54 six used Rome criteria, 55 and the remaining 35 trials used either symptoms of IBS, or defined one, two, or three symptoms of IBS as entry criteria. Classification into diarrhoea predominant and constipation predominant categories appears to reflect physiological diVerences between each type. 56 For studies on prokinetic drugs, [37] [38] [39] entry criteria required patients to have constipation predominant symptoms. However, of seven antidiarrhoeal trials only one used the presence of diarrhoea predominant IBS as an entry criterion.
It is recommended that patients meet clear standardised entry criteria to be included in trials. Talley and colleagues 57 recommend the use of the Rome criteria. The authors also recommend that limiting trials to defined subgroups of patients should be considered to enhance homogeneity of the study population.
STUDY DESIGN
Considerations that are especially relevant to the design of controlled treatment trials for IBS are the use of placebo control, study duration, baseline comparisons, maintaining blindedness, and the appropriateness of the commonly used crossover design. There were a number of common problems with the studies identified. A major problem with designing RCTs for the treatment of IBS is the placebo response, which is extremely variable and high, most frequently between 40% and 70%. 58 This was a particular problem in three studies reported in table 1. 7 9 11 DiVerences of this magnitude reflect not only the nature of the patients enrolled in a trial but the methods used to determine treatment response. It is impossible to be certain that even marked improvements are due to the intrinsic properties of the treatment being tested unless there is a placebo control group. Therefore, it is recommended that all IBS trials be placebo controlled. 57 58 All of the trials included clearly mentioned the number of patients given either treatment or placebo. One study provided incomplete information concerning the number of dropouts 40 and one study failed to mention the number of dropouts. 29 
RANDOMISATION
All of the 45 studies were considered to be RCTs yet only seven mentioned the method of randomisation. 10 11 17 22 27 30 31 The other 40 trials may have been appropriately randomised yet failed to describe the method of randomisation. It is considered important not only to describe the method of randomisation but also to provide information regarding the frequency of a variety of characteristics in the treatment and control groups to ensure adequate similarity between the two groups. 57 
BLINDING
Forty one of 47 RCTs were double blinded. None of the four studies [26] [27] [28] [29] on combinations of drugs with bulking agents or high fibre diet were blinded. This was expected as it would be diYcult to achieve blinding in such studies. No blinding was possible in the study of Shaw and colleagues 24 in which peppermint oil treatment was compared with a stress management programme. Talley and colleagues 57 recommend that all IBS trials are double blinded. Where this is not possible such as in non-drugs trials of treatments such as psychotherapy, it is essential that independent evaluators are used to rate the eVectiveness of treatment.
TREATMENT PERIOD (DURATION OF TRIALS) IBS is usually a chronic, sometimes lifelong, condition with unpredictable periods of exacerbation and remission. Thus clinical trials of only a few days or weeks are of limited relevance for establishing that a treatment is eVective. As can be seen from table 1, the majority of IBS treatment trials were of insuYcient duration to be clinically relevant. The studies that fulfilled the Jadad criteria 1 reported treatment periods varying from one month 22 to six months. 27 In all 45 trials, the duration of the treatment period is clearly mentioned together with any washout period in the crossover trials. It is recommended that trials of IBS treatments be a minimum of 8-12 weeks' duration. 57 Maxton and colleagues 59 suggest a total trial duration of approximately 12 weeks.
OUTCOME MEASURES
Because there are no objective markers in improvement of IBS, determination of eYcacy in treatment trials is based on somewhat arbitrary rating scales. A change in abdominal pain, bowel habit, and overall well being are the main outcome measures used in IBS trials, with distension tending to be neglected, although patients often perceive it as severe. 58 The studies reported here used a range of outcome measures, including nausea, vomiting, abdominal pain (frequency, severity, and duration), bowel habit (frequency, consistency of stools, and transit time), distension, and overall symptom scores, as assessed by the patient or physician. Specific measures were also used, appropriate to the therapeutic agent. For example, in a tricyclic antidepressant study, a standard measure of depression (Hamilton-D score) was used as it was anticipated that a significant proportion of enrolled patients would be depressed. 30 Northcutt and colleagues 60 used adequate pain relief as an outcome measure in their study of alosteron, a 5-HT 3 receptor antagonist. In a review, Talley and colleagues 57 strongly proposed the need to develop sensitive symptom outcome measures as a priority among their recommendations to optimise IBS trials. The authors recommended that symptom outcome measures should include multiple domains and that quality of life should be assessed in addition to gastrointestinal symptoms. They also suggest that global assessment scales are useful although further research is needed to determine the degree to which global well being and health or symptoms are correlated. If resources to expand the treatment of IBS are to be found, future studies will need to include generic quality of life measures to allow comparison with eVects in completely diVerent therapeutic areas.
REVIEWS OF IBS TREATMENTS
No Cochrane review of IBS treatments was identified in this review. However, other reviews have highlighted the flaws in IBS study design. For example, Pace and colleagues, 61 in a review of fibre supplementation, found the studies to be flawed due to high placebo response, small sample size, short duration of treatment, inadequate dose or mode of fibre delivery, and ill defined inclusion criteria. The authors also found that in the five antidepressant studies reviewed, all had methodological and statistical problems.
A recent meta-analysis by Pittler and Ernst 62 reported that the role of peppermint oil in the symptomatic treatment of IBS has not been established and carefully executed studies are needed to clarify the issue. In a review of anticholinergics, all eight studies were judged to be flawed and with conflicting results. 61 A meta-analysis of 26 selected double blind, randomised trials was performed by Poynard and colleagues 63 which included eight drugs: cimetropium bromide, dicyclomine hydrochloride, mebeverine, hyoscine butyl bromide, octylonium bromide, peppermint oil, pinaverium bromide, and trimebutine. Only five drugs (cimetropium bromide, mebeverine, octylonium bromide, pinaverium bromide, and trimebutine) have been shown to be clinically eVective in patients with IBS without adverse reactions.
Conclusions
IBS is a challenging disorder that aVects many individuals, and its treatment is extremely complex. A variety of processes appear to be at work and IBS suVerers are not a homogeneous population. Therefore, not all treatments will be suitable for all IBS patients. Rather, certain interventions will be eVective towards specific aspects of IBS.
The literature review of treatments for IBS identified few RCTs and a poor overall quality of research. The majority of published trials failed to meet even simple criteria for acceptability. Despite this, a variety of interventions have been shown to be clinically eVective in the treatment of symptoms of IBS, although no drug is eVective in treating all symptoms. A variety of outcome measures have been used, making it diYcult to compare the results of trials.
Several new drugs are currently being developed which show promise in the treatment of IBS. 64 It is essential that RCTs are conducted of consistently identified patients with clearly defined outcome measures. These outcome measures should not only deal with symptom relief but also improvement in quality of life and associated measures such as time oV work.
